Epilepsy device pushes up Cyberonics sales
This article was originally published in Clinica
Cyberonics, which markets an implantable vagus nerve stimulation device for epilepsy treatment, has recorded a 287% sales increase to $1.1 million in the first quarter. $554,000 of the sales were generated in the US, where the product, known as the NeuroCybernetic Prosthesis system, was launched this summer (see Clinica No 766, p 15).
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.